Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 49OTHER 43NIH 4OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Recurrence 1Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Gemcitabine 4Cisplatin 4Rituximab 2Fluorouracil 2Everolimus 2tislelizumab 1phosphorylethanolamine 1parsaclisib 1human papillomavirus vaccine, L1 type 16, 18 1famitinib 1dalpiciclib 1Zinc Sulfate 1Zinc 1Vitamin B 6 1Tamoxifen 1Sunitinib 1Sorafenib 1Radiotherapy, Adjuvant 1Pyridoxine 1Proton Pump Inhibitors 1Prednisone 1Platelet Transfusion 1Photochemotherapy 1Pemetrexed 1Patient Portals 1Paclitaxel 1Oxaliplatin 1Neoadjuvant Therapy 1N-hydroxy-4-acetylaminostilbene 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER_GOV × Azacitidine × Clear all
NCT00412919 2013-12-16

Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma

Bayside Health

Phase 2 Terminated
7 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡